Potential Noninvasive Wet AMD Treatments, Fuchs Dystrophy Genetic Link, Technology Obstacles
In this week's EyewireTV, the INTREPID study, which examined Oraya Therapeutics’ radiation therapy for the treatment of wet AMD, has met its primary endpoint; and research confirms that a genetic factor is a strong predictor of an individual’s risk of developing Fuchs dystrophy. In the weekly feature, industry and venture capital executives share their thoughts on overcoming the challenges involved in bringing new technology to the marketplace.
VEGF Trap-Eye Improves Vision in Diabetic Eye Disease
From Medscape Ophthalmology
Vascular Endothelial Growth Factor (VEGF) Trap-Eye provided a significant benefit to patients with diabetic macular edema in a phase II trial - and updated data now shows the initial improvements were sustained or increased a year later. The 24-week results of the DA VINCI study, published in 2011, showed that VEGF Trap-Eye intravitreal injections ...
Read full articleThursday, May 17, 2012
NovaBay Enrolls First Patients in Global BAYnovation Phase 2...
From NovaBay Pharmaceuticals, Inc. — 5/17/2012
NovaBay Pharmaceuticals, Inc., announced that it has enrolled the first patients in its global Phase 2b clinical study. The study (named BAYnovation) ...Full story

Smartphones Can Help the Visually Impaired, but Many Doctors...
From Loyola University Health System — 5/17/2012
iPhones and other smartphones can be a huge help to the visually impaired, but few vision doctors are recommending them to patients, according to a st...Full story
Lutein, Zeaxanthin May Reduce Cataract Risk: Study
From Nutra Ingredients — 5/17/2012
Lutein and Zeaxanthin may protect the lens of the eye from oxidative stress and reduce the risk of cataract, says a new study. The protective effect o...Full story
Optical Coherence Tomography Useful for Macular Edema
From Medscape Today — 5/17/2012
In patients with diabetic macular edema, visual acuity (VA) correlates with the magnitude of change in central macular thickness (CMT). The strongest ...Full story
Wednesday, May 16, 2012
Eye Cancer Tumors Likely To Spread Can Be Identified By Gene...
From Medical News Today — 5/16/2012
Researchers at Washington University School of Medicine in St. Louis have developed a genetic test that can accurately predict whether the most common...Full story
Can PlusoptiX Replace Cycloplegic Exams in Young Children?
From Medscape Ophthalmology — 5/16/2012
Do children who have had undilated plusoptiX exams also need to have dilated exams to make sure that abnormalities have not been overlooked? That is t...Full story
Genentech to Test Alzheimer's Drug on Healthy Patients in Hi...
From Oakland Tribune — 5/16/2012
Roche's Genentech unit has won the right to try its experimental Alzheimer's drug crenezumab on people with no signs of dementia -- the first such tri...Full story
Docs Win Most Malpractice Cases at Trial
From Medpage Today — 5/16/2012
Plaintiffs hardly ever win medical malpractice cases that go all the way to a jury verdict, and only 4.5% of claims filed ever go that far, researcher...Full story
Tuesday, May 15, 2012
Pacific Cataract and Laser Institute Sees Big Benefits with ...
From Pacific Cataract and Laser Institute — 5/15/2012
Anoto and NextGen Healthcare Information Systems LLC announced that Pacific Cataract and Laser Institute is capturing new patient registration informa...Full story
Vision Loss Due To Degenerative Eye Diseases May Be Restored...
From Medical News Today — 5/15/2012
Using tiny solar-panel-like cells surgically placed underneath the retina, scientists at the Stanford University School of Medicine have devised a sys...Full story
Topical Antibiotics Boost Risk of Endophthalmitis After Eye ...
From Medscape Today — 5/15/2012
After intravitreal injections of anti-vascular endothelial growth factors or triamcinolone, topical antibiotics might actually be unhelpful, a new pap...Full story
Changes in Eye Vessels Signal Heart Troubles
From Medpage Today — 5/15/2012
Changes in diameter of the tiny blood vessels in the retina predicted the later development of cardiovascular disease in African Americans with type 1...Full story
Carl Zeiss Meditec Continues its Profitable Growth
From Carl Zeiss Meditec AG — 5/15/2012
Medical technology provider Carl Zeiss Meditec generated growth of 14.8% in the first six months of financial year 2011/2012. The company posted reven...Full story
Eye Changes May Predict Heart Disease in Blacks With Diabete...
From US News & Health Report — 5/15/2012
In black Americans with type 1 diabetes, narrowing of the small arteries in the eye's retina (retinal arteriolar narrowing) is associated with increas...Full story
Monday, May 14, 2012
Bausch + Lomb Names John Barr Global President Surgical
From Bausch + Lomb — 5/14/2012
Bausch + Lomb has named John Barr Global President of the company's surgical business. In this capacity, Mr. Barr will oversee the company's full suit...Full story
New Advances In Treating Inherited Retinal Diseases
From Medical News Today — 5/14/2012
Gene therapy strategies to prevent and treat inherited diseases of the retina that can cause blindness have progressed rapidly. Positive results in an...Full story
Two Glaucoma Implants Equally Good at 3 Years
From Medscape Today — 5/14/2012
The Ahmed glaucoma valve and the Baerveldt glaucoma implant, the 2 most commonly used glaucoma drainage implants in the United States, are equally suc...Full story
Lights On or Off for Pediatric Red Reflex Exam?
From Medscape Ophthalmology — 5/14/2012
Pediatricians detect ocular disease in infants and children using the red reflex exam, but does it underestimate the presence of that disease? That's ...Full story
FDA Grants Fast Track Designation to Ohr Pharmaceutical's Sq...
From Ohr Pharmaceutical — 5/14/2012
Ohr Pharmaceutical Inc. announced that its Squalamine Eye Drops, a potent inhibitor of multiple growth factors implicated in angiogenesis, has been aw...Full story
New Type of Retinal Prosthesis Could Better Restore Sight to...
From Stanford University Medical Center — 5/14/2012
Using tiny solar-panel-like cells surgically placed underneath the retina, scientists at the Stanford University School of Medicine have devised a sys...Full story
Friday, May 11, 2012
Optos Continues to Demonstrate Strong Clinical Evidence
From Optos PLC — 5/11/2012
Optos PLC announced the presentation of more than 50 positive clinical studies at ARVO. The clinical studies involved clinical sites from 49 academic ...Full story
Besifloxacin Demonstrated Potent Activity, High Rate of Erad...
From Bausch + Lomb — 5/11/2012
The antibiotic besifloxacin demonstrated potent activity and high rates of eradication against problematic multi-drug resistant organisms that cause e...Full story
Advanced Loteprednol Etabonate Gel Formulation May Offer New...
From Bausch + Lomb — 5/11/2012
Bausch + Lomb announced that its new loteprednol etabonate (LE) gel formulation demonstrated safety and efficacy for the treatment of ocular inflammat...Full story
Amakem Appoints Dr. Steve Pakola as Chief Medical Officer; D...
From Amakem NV — 5/11/2012
Amakem NV, a kinase platform company focusing on ophthalmology, today announces the appointment of Dr. Steve Pakola as Chief Medical Officer and Dr. G...Full story
Thrombogenics: Announces Business Update
From 4-Traders — 5/11/2012
ThromboGenics signed an important strategic deal with Alcon, the global leader in eye care, to commercialize ocriplasmin outside the U.S. ThromboGenic...Full story
High-Dose Ranibizumab No Better Than Standard Dose for AMD
From Medscape Today — 5/11/2012
High-dose ranibizumab (Lucentis) does not provide better visual acuity than standard-dose ranibizumab in newly diagnosed wet age-related macular degen...Full story
Researchers Present Data Highlighting Potential of Peregrine...
From Peregrine Pharmaceuticals, Inc. — 5/11/2012
Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diag...Full story
Thursday, May 10, 2012
Seven Scientific Posters Sponsored by TearScience at ARVO Ad...
From TearScience, Inc. — 5/10/2012
TearScience Inc. announced that it sponsored research for seven scientific posters on evaporative dry eye and its technology at ARVO. Subjects reflect...Full story
Ista Pharmaceuticals Highlights Prolensa Clinical Data at AR...
From Ista Pharmaceuticals Inc. — 5/10/2012
Ista Pharmaceuticals, Inc. presented results from the second of two phase 3 studies of Prolensa (bromfenac ophthalmic solution), the company's once-da...Full story
Topical Aganirsen Found To Be Active In Retinal Disease
From Medical News Today — 5/10/2012
Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, has announced that positive data from a study o...Full story
Retinopathy Screenings Can Be Less Frequent
From Medscape Today — 5/10/2012
Screening for retinopathy every 2 years instead of the recommended annual screening would be safe and could reduce screening costs by about 25% for pe...Full story
Bill Would Repeal SGR, Phase Out Medicare Fee-for-Service
From Medscape Today — 5/10/2012
A bipartisan bill introduced in the House today would avert a Medicare pay cut of roughly 30% in 2013 by repealing the program's sustainable growth ra...Full story
Hoya Reports Fourth Quarter and Full-Year Financial Results
From Hoya — 5/10/2012
Hoya Corp. announced financial results for the fourth quarter and full-year ended March 31, 2012. For the quarter under review, revenues from all oper...Full story
Retinal Microchip Restores Vision in Retinitis Pigmentosa
From Medscape Today — 5/10/2012
A subretinal microchip implant has entered new clinical trials in the United Kingdom and Hong Kong, and early results are encouraging, according to re...Full story




